Between January and March 2018, Russia exported 5.05 bln RUB worth of ready-made drugs (custom clearance prices), the EEU countries excluded. In monetary terms, this is 1.2% higher than that of the same period of 2017. In physical terms, the dynamics are -3.7%, with 0.12 bln units. When calculated in minimum dosage units (MDU), the dynamics are -9%.

Russia exports not only self-produced pharmaceuticals, but also the imported ones. Between January and March 2018, self-produced pharmaceuticals took up around 62% of the export, while the rest was either imported products or export to certain unrecognized or partially recognized regions, when the producing companies are often unaware of their products being resold.

Between January and March 2018, Russia exported pharmaceuticals to 54 countries. The absolute leader in monetary terms is still Ukraine, mainly Donetsk People's Republic and Luhansk People’s Republic, with 31.4% of the export. In physical terms, the leader is Uzbekistan, with 35.4%. Bulgaria and Serbia take up the lowest amount of the Russian pharmaceutical export, with less than 10,000 RUB.

Immunostimulative drug Ribunyl (Pierre Fabre) has highest dynamics in monetary terms over the period, with a nearly 5,000 times increase. However, it is not exactly export but the return of the imported drug. This is also the case for Zoladex (AstraZeneca), with a 1,000 times increase. Inactivated split influenza virus vaccine (Saint Petersburg Vaccine and Serum Institute), which was exported to Turkey, showed the worst dynamics, with -69%.

Dynamics of pharmaceutical drug export from Russia (EEU countries excluded) (2016 – 2017, January – March 2018), bln RUB